BioMarin and n-Lorem partner on early research for ReNU syndrome therapy

Summary

BioMarin Pharmaceutical and n-Lorem Foundation have entered a collaboration and licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome. The partnership focuses on early research for this rare disease indication.